Cargando…
No effects of mitomycin-C in primary trabeculectomies in Sweden
AIM: To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C. MATERIALS AND METHODS: This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Ska...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024500/ https://www.ncbi.nlm.nih.gov/pubmed/29977549 http://dx.doi.org/10.1177/2050312118782262 |
_version_ | 1783336068135780352 |
---|---|
author | Ayala, Marcelo |
author_facet | Ayala, Marcelo |
author_sort | Ayala, Marcelo |
collection | PubMed |
description | AIM: To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C. MATERIALS AND METHODS: This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Skaraborg Hospital, Skövde, Sweden. Complete success was defined as intraocular pressure ⩽18 mmHg (criterion 1) or intraocular pressure reduction ⩾30% (criterion 2) without eye drops postoperatively. Qualified success was defined using the same criteria (1 and 2), but patients were treated or untreated with eye-drops. RESULTS: A total of 167 patients were included in this retrospective study, 83 patients in the no-mitomycin-C group and 84 patients in the mitomycin-C-treated group. No significant difference was found in intraocular pressure reduction between the mitomycin-C and no-mitomycin-C group (t-test; p = 0.19). Complete success using criterion 1 was 66.2% in no-mitomycin-C and 62.8% in mitomycin-C (p = 0.88); success using criterion 2 was 76.6% in the no-mitomycin-C and 64.2% in the mitomycin-C group (p = 0.21). Qualified success using criterion 1 was 71.4% in the no-mitomycin-C and 74.4% in the mitomycin-C group (p = 0.84); success using criterion 2 was 80.0% in the no-mitomycin-C and 84.4% in the mitomycin-C group. All included patients were born in Sweden. CONCLUSION: Mitomycin-C seems to add no benefits to intraocular pressure reduction after primary trabeculectomies in a Swedish population. |
format | Online Article Text |
id | pubmed-6024500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60245002018-07-05 No effects of mitomycin-C in primary trabeculectomies in Sweden Ayala, Marcelo SAGE Open Med Original Article AIM: To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C. MATERIALS AND METHODS: This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Skaraborg Hospital, Skövde, Sweden. Complete success was defined as intraocular pressure ⩽18 mmHg (criterion 1) or intraocular pressure reduction ⩾30% (criterion 2) without eye drops postoperatively. Qualified success was defined using the same criteria (1 and 2), but patients were treated or untreated with eye-drops. RESULTS: A total of 167 patients were included in this retrospective study, 83 patients in the no-mitomycin-C group and 84 patients in the mitomycin-C-treated group. No significant difference was found in intraocular pressure reduction between the mitomycin-C and no-mitomycin-C group (t-test; p = 0.19). Complete success using criterion 1 was 66.2% in no-mitomycin-C and 62.8% in mitomycin-C (p = 0.88); success using criterion 2 was 76.6% in the no-mitomycin-C and 64.2% in the mitomycin-C group (p = 0.21). Qualified success using criterion 1 was 71.4% in the no-mitomycin-C and 74.4% in the mitomycin-C group (p = 0.84); success using criterion 2 was 80.0% in the no-mitomycin-C and 84.4% in the mitomycin-C group. All included patients were born in Sweden. CONCLUSION: Mitomycin-C seems to add no benefits to intraocular pressure reduction after primary trabeculectomies in a Swedish population. SAGE Publications 2018-06-18 /pmc/articles/PMC6024500/ /pubmed/29977549 http://dx.doi.org/10.1177/2050312118782262 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Ayala, Marcelo No effects of mitomycin-C in primary trabeculectomies in Sweden |
title | No effects of mitomycin-C in primary trabeculectomies in Sweden |
title_full | No effects of mitomycin-C in primary trabeculectomies in Sweden |
title_fullStr | No effects of mitomycin-C in primary trabeculectomies in Sweden |
title_full_unstemmed | No effects of mitomycin-C in primary trabeculectomies in Sweden |
title_short | No effects of mitomycin-C in primary trabeculectomies in Sweden |
title_sort | no effects of mitomycin-c in primary trabeculectomies in sweden |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024500/ https://www.ncbi.nlm.nih.gov/pubmed/29977549 http://dx.doi.org/10.1177/2050312118782262 |
work_keys_str_mv | AT ayalamarcelo noeffectsofmitomycincinprimarytrabeculectomiesinsweden |